- •We explore a protective effect in diabetics of hyperglycemia in critical illness.
- •It’s the first to investigate the influence of diabetes on the outcome of sepsis.
- •Two mechanisms for the protective effect are proposed.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Diabetes Research and Clinical Practice
- Hyperglycemia and outcomes of medical intensive care unit patients with and without a history of diabetes mellitus in a Chinese population.Intens Care Med. 2017; 43: 144-145
- Diabetes mellitus does not adversely affect outcomes from a critical illness.Crit Care Med. 2010; 38: 16-24
Vincent JL, Preiser JC, Sprung CL, Moreno R, Sakr Y. Insulin-treated diabetes is not associated with increased mortality in critically ill patients. Critical care (London, England). 2010;14:R12.
- Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis.Crit Care Med. 2010; 38: 539-545
Esper AM, Moss M, Martin GS. The effect of diabetes mellitus on organ dysfunction with sepsis: an epidemiological study. Critical care (London, England). 2009;13:R18.
- The diabetes paradox: diabetes is not independently associated with mortality in critically ill patients.Hospital Practice. 1995; 2012: 31-35
- Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis.Crit Care Med. 2009; 37: 3001-3009
- Diabetes patients and non-diabetic patients intensive care unit and hospital mortality risks associated with sepsis.World J Diabetes. 2012; 3: 29-34
- Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality.Intens Care Med. 2014; 40: 973-980
- Intensive insulin therapy in critically ill patients.New England J Med. 2001; 345: 1359-1367
- Intensive insulin therapy in the medical ICU.New England J Med. 2006; 354: 449-461
- Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control.Crit Care Med. 2003; 31: 359-366
- Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm.Diabetes. 2006; 55: 3151-3159
- Management of diabetes and hyperglycemia in hospitals.Diabetes Care. 2004; 27: 553-591
Executive summary: standards of medical care in diabetes–2014. Diabetes care. 2014;37 Suppl 1:S5–13.
- Respiratory variations in the arterial pressure during mechanical ventilation reflect volume status and fluid responsiveness.Intens Care Med. 2014; 40: 798-807
- What's new: the management of acute right ventricular decompensation of chronic pulmonary hypertension.Intens Care Med. 2014; 40: 1930-1933
- Variability of blood glucose concentration and short-term mortality in critically ill patients.Anesthesiology. 2006; 105: 244-252
- Glycaemic variability, infections and mortality in a medical-surgical intensive care unit.Critic Care Resuscitation: J Aust Academy Critic Care Med. 2014; 16: 13-23
- Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.Am J Respir Crit Care Med. 2001; 164: 396-402
- Can the interleukin-6 response to endotoxin be predicted? Studies of the influence of a promoter polymorphism of the interleukin-6 gene, gender, the density of the endotoxin receptor CD14, and inflammatory cytokines.Crit Care Med. 2002; 30: 664-669
- Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans.Am J Physiol Endocrinol Metab. 2002; 282: E1276-E1285
- Interleukin 6 stimulates hepatic glucose release from prelabeled glycogen pools.Am J Physiol. 1990; 258: E57-E64
- Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro.Diabetes. 1996; 45: 954-959
- Downregulation of proinflammatory cytokine release in whole blood from septic patients.Blood. 1995; 85: 1341-1347
- Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases.New England J Med. 1997; 336: 1066-1071
- Activators and target genes of Rel/NF-kappaB transcription factors.Oncogene. 1999; 18: 6853-6866
- Role of NFkappaB in the mortality of sepsis.J Clin Investig. 1997; 100: 972-985
- Predictive value of nuclear factor kappaB activity and plasma cytokine levels in patients with sepsis.Infect Immun. 2000; 68: 1942-1945
- Increased nuclear factor kappa B activation in critically ill patients who die.Crit Care Med. 2000; 28: 1047-1051
- Effect of increased concentration of D-glucose or L-fucose on monocyte adhesion to endothelial cell monolayers and activation of nuclear factor-kappaB.Metab Clin Exp. 2002; 51: 225-234
Marik PE, Varon J. Sepsis: state of the art. Disease-a-month: DM. 2001;47:465–532.
- Sepsis: a new hypothesis for pathogenesis of the disease process.Chest. 1997; 112: 235-243
- Biochemistry and molecular cell biology of diabetic complications.Nature. 2001; 414: 813-820
- Hyperglycemia and lipopolysaccharide decrease depression effect of interleukin 8 production by hypothermia: an experimental study with endothelial cells.Intens Care Med. 2008; 34: 109-115
- Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia.Metab Clin Exp. 1999; 48: 1503-1508
- Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria.Diabetes Care. 2010; 33: 2184-2189
- Tight computerized versus conventional glucose control in the ICU: a randomized controlled trial.Intens Care Med. 2014; 40 (Comment on Kalfon et al): 922
- Year in review in intensive care medicine 2012: I. Neurology and neurointensive care, epidemiology and nephrology, biomarkers and inflammation, nutrition, experimentals.Intens Care Med. 2013; 39: 232-246
- What's new in glucose control in the ICU?.Intens Care Med. 2013; 39: 823-825